RxCell has announced a US patent for its induced pluripotent stem cells (iPSCs)-based cell therapy approach, a method of ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

Through TF-based cell fate programming, TFome is designed to yield first-in-class and best-in-class off-the-shelf cell therapy products up to 100 times more rapidly than conventional methods of cell ...

The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Trailhead Biosystems Inc. announced Monday, Sept. 16, that it has hired Joshua Snow as chief commercial officer. The ...

On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated compliance with Listing Rule 5550 (b) (1) (the “Equity Rule”) of The Nasdaq Stock Market.

Northeast Florida health care systems share some of their innovative offerings available now or in the pipeline.

Dr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...

Think of Bangkok and one of the first things that come to mind is cheap massages. But let's face it — a quick rub down isn't ...